Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.51 |
| ▸ | CTSB | P07858 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24690562 | 1.00 | CTSL (0.51) | CTSLCTSB | |
| SCHEMBL28732896 | 1.00 | CTSL (0.51) | CTSLCTSB | |
| SCHEMBL24583074 | 0.94 | REN (0.47) | CTSLCTSB | |
| SCHEMBL30819685 | 0.93 | CTSL (0.46) | CTSLCTSB | |
| SCHEMBL19586866 | 0.91 | CTSL (0.54) | CTSLCTSB | |
| SCHEMBL19586870 | 0.91 | CTSL (0.54) | CTSLCTSB | |
| SCHEMBL19586868 | 0.91 | CTSL (0.54) | CTSLCTSB | |
| SCHEMBL24113103 | 0.91 | CTSL (0.42) | CTSL | |
| SCHEMBL24020461 | 0.91 | CTSL (0.42) | CTSL | |
| SCHEMBL24013950 | 0.91 | CTSL (0.42) | CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122153-A1 | Protease Inhibitors as Antivirals | ACEA Therapeutics, Inc. (US) | 2025-04-17 | — | — | US | disclosed |
| US-11987554-B2 | Protease inhibitors as antivirals | VIVASOR, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| CN-114681443-B | Nitrile-containing antiviral compounds | 辉瑞大药厂 | 2024-05-10 | — | — | CN | disclosed |
| EP-4347034-A1 | PROTEASE INHIBITORS AS ANTIVIRALS | ACEA Therapeutics, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| US-20230322668-A1 | PROTEASE INHIBITORS AS ANTIVIRALS | ACEA Therapeutics, Inc. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322668-A1 | PROTEASE INHIBITORS AS ANTIVIRALS | ACEA Therapeutics, Inc. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322668-A1 | PROTEASE INHIBITORS AS ANTIVIRALS | ACEA Therapeutics, Inc. (US) | 2023-10-12 | — | — | US | disclosed |
| CN-116789648-A | Nitrile-containing antiviral compounds | 辉瑞大药厂 | 2023-09-22 | — | — | CN | disclosed |
| US-11753373-B2 | Protease inhibitors as antivirals | ACEA Therapeutics, Inc. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753373-B2 | Protease inhibitors as antivirals | ACEA Therapeutics, Inc. (US) | 2023-09-12 | — | — | US | disclosed |
| CN-114466838-B | Nitrile-containing antiviral compounds | 辉瑞大药厂 | 2023-05-02 | — | — | CN | disclosed |
| US-20230026438-A1 | PROTEASE INHIBITORS AS ANTIVIRALS | ACEA Therapeutics, Inc. | 2023-01-26 | — | — | US | disclosed |
| US-20230026438-A1 | PROTEASE INHIBITORS AS ANTIVIRALS | ACEA Therapeutics, Inc. | 2023-01-26 | — | — | US | disclosed |
| WO-2022256434-A1 | PROTEASE INHIBITORS AS ANTIVIRALS | ACEA Therapeutics, Inc. (US) | 2022-12-08 | — | — | WO | disclosed |
| WO-2022256434-A1 | PROTEASE INHIBITORS AS ANTIVIRALS | ACEA Therapeutics, Inc. (US) | 2022-12-08 | — | — | WO | disclosed |
| US-11452711-B2 | Nitrile-containing antiviral compounds | PFIZER INC. (US) | 2022-09-27 | — | — | US | disclosed |
| CN-114681443-A | Nitrile-containing antiviral compounds | 辉瑞大药厂 | 2022-07-01 | — | — | CN | disclosed |
| US-11351149-B2 | Nitrile-containing antiviral compounds | PFIZER INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20220142976-A1 | Nitrile-Containing Antiviral Compounds | PFIZER INC. (US) | 2022-05-12 | — | — | US | disclosed |
| CN-114466838-A | Nitrile-containing antiviral compounds | 辉瑞大药厂 | 2022-05-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122153-A1 | Protease Inhibitors as Antivirals | ACE, ACE2, TMPRSS15 | CTSL 4/4885CTSB 44/4885 |
| US-20230026438-A1 | PROTEASE INHIBITORS AS ANTIVIRALS | ACE, ACE2, TMPRSS15 | CTSL 4/4885CTSB 44/4885 |
| US-11452711-B2 | Nitrile-containing antiviral compounds | ACE2, NOS2, EIF2AK2 | CTSL 635/4885CTSB 657/4885 |
| US-20220142976-A1 | Nitrile-Containing Antiviral Compounds | ACE2, NOS2, EIF2AK2 | CTSL 635/4885CTSB 657/4885 |
| US-11753373-B2 | Protease inhibitors as antivirals | ACE, ACE2, TMPRSS15 | CTSL 4/4885CTSB 44/4885 |
| US-11987554-B2 | Protease inhibitors as antivirals | ACE, ACE2, TMPRSS15 | CTSL 4/4885CTSB 44/4885 |
| US-11351149-B2 | Nitrile-containing antiviral compounds | ACE2, NOS2, EIF2AK2 | CTSL 635/4885CTSB 657/4885 |
| US-20230322668-A1 | PROTEASE INHIBITORS AS ANTIVIRALS | ACE, ACE2, TMPRSS15 | CTSL 4/4885CTSB 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.